Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Doolin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology in Drug Development|September 27, 2025
The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric DiseasePaul Rolan, Elizabeth Doolin, Dharam Paul, et al.
NEJM Evidence|December 8, 2024
BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress DisorderSpyridon Papapetropoulos, Elizabeth Doolin, Susan O'Connor, et al.
Psychiatry Research|February 15, 2025
A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL studySpyros Papapetropoulos, Elizabeth Doolin, Michael Odontiadis, et al.
Translational Psychiatry|January 8, 2021
Cholinergic modulation of disorder-relevant human defensive behaviour in generalised anxiety disorderAdam Perkins, Fiona Patrick, Toby Wise, et al.
Biological Psychiatry|February 29, 2020
Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety DisorderToby Wise, Fiona Patrick, Nicholas Meyer, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2018
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)Kristina Lindemann, Philip J Beale, Emma Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology in Drug Development|September 27, 2025
The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric DiseasePaul Rolan, Elizabeth Doolin, Dharam Paul, et al.
NEJM Evidence|December 8, 2024
BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress DisorderSpyridon Papapetropoulos, Elizabeth Doolin, Susan O'Connor, et al.
Psychiatry Research|February 15, 2025
A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL studySpyros Papapetropoulos, Elizabeth Doolin, Michael Odontiadis, et al.
Translational Psychiatry|January 8, 2021
Cholinergic modulation of disorder-relevant human defensive behaviour in generalised anxiety disorderAdam Perkins, Fiona Patrick, Toby Wise, et al.
Biological Psychiatry|February 29, 2020
Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety DisorderToby Wise, Fiona Patrick, Nicholas Meyer, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2018
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)Kristina Lindemann, Philip J Beale, Emma Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.
Pageof 1